Highlights The overall incidence of febrile neutropenia in the study population was 13.4% (31 cases) Brand-name docetaxel (Taxotere®) use was the only factor associated with the occurrence of febrile neutropenia. No statistically significant differences in progression-free survival rates between brand-name and generic docetaxel. ABSTRACT Objective: To assess the incidence of febrile neutropenia without primary granulocyte colonystimulating factor prophylaxis in patients undergoing chemotherapy with adjuvant docetaxel and cyclophosphamide, and to evaluate the toxicity profile of brand-name docetaxel (Taxotere®) and the generic […]